Experimental intraperitoneal infusion of OK-432 in rats: evaluation of peritoneal complications and pathology.
OBJECTIVE
OK-432 is known to be a potent sclerosant of cystic lesions. The purpose of this study was to evaluate both its safety and pathologic effects after the infusion of OK-432 into the peritoneal cavity of rats.


METHODS
Twenty male rats were used in this study. Twelve rats were infused intraperitoneally with 0.2 Klinishe Einheit of OK-432 melted in 2 mL of normal saline (group 1: the treated group); four rats each were infused intraperitoneally with 0.5 mL of 99% ethanol (group 2) and normal saline (group 3), and served as the control groups. An abdominal ultrasonographic examination was performed both before and after the infusions in all rats. Three rats in group 1 and one rat in each of groups 2 and 3 were sacrificed each week following the infusion. Gross and microscopic evaluations of the peritoneum and abdominal cavity were performed on each rat.


RESULTS
In group 1, the abdomen was clear on gross inspection and the peritoneum was unremarkable on microscopic examination. In group 2, mild-to-moderate peritoneal adhesions were revealed grossly, and inflammation and fibrosis of the peritoneum were demonstrated microscopically. In group 3, no specific abnormalities were noted on gross or microscopic examinations.


CONCLUSIONS
Leakage or abnormal infusion of OK-432 solution into the peritoneal cavity during sclerotherapy of intra-abdominal or retroperitoneal cystic lesions does not result in any significant complications.
Kim
Dong Wook
DW
Department of Radiology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Kim
Hak Jin
HJ
Lee
Jun Woo
JW
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007263:Infusions, Parenteral; D008297:Male; D010532:Peritoneal Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D010537:Peritoneum / Q000000981:diagnostic imaging* / Q000187:drug effects*; D010844:Picibanil / Q000008:administration & dosage* / Q000009:adverse effects*; D051381:Rats; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects; D014463:Ultrasonography
D000970:Antineoplastic Agents; D012597:Sclerosing Solutions; D010844:Picibanil